Gross R, Hirschmann W D
Arzneimittelforschung. 1976;26(1A):130-5.
The clinical application of cytostatic drugs requires knowledge of their biochemistry, pharmacology, pharmacokinetics as well as their action at the cellular level within the generation cycle. The principles apply to tumor cells as well as to normal, rapidly proliferating tissues. The intensive research on cancer treatment all over the world is leading to a rapid accumulation of experimental data about the action of single cytostatic drugs in tissue culture and on transplantable animal tumor systems, especially in rodents. Clinical chemotherapy in human malignancies today preferentially uses combinations of different cytostatics. Inumerable combinations of drugs are available, especially if variations in respect to drug dose and intervals of drug application are taken into consideration. The experimental basis for such combinations of drugs and drug interactions is scanty. Using the pyrimidine analog cytosine arabinoside and the two antibiotics daunorubicin and doxyrubicin (adriamycin) as examples, it is demonstrated that information on the pharmacolinetic behaviour of cytostatic drugs is a prerequisite for their success in clinical application, but is on its own insufficient to predict the tumor response.
细胞抑制药物的临床应用需要了解其生物化学、药理学、药代动力学以及它们在细胞周期内细胞水平的作用。这些原则适用于肿瘤细胞以及正常的快速增殖组织。全世界对癌症治疗的深入研究导致关于单一细胞抑制药物在组织培养和可移植动物肿瘤系统（特别是在啮齿动物中）作用的实验数据迅速积累。当今人类恶性肿瘤的临床化疗优先使用不同细胞抑制剂的组合。有无数种药物组合可供选择，尤其是如果考虑到药物剂量和用药间隔的变化。此类药物组合和药物相互作用的实验依据很少。以嘧啶类似物阿糖胞苷以及两种抗生素柔红霉素和阿霉素（阿德里亚霉素）为例，证明了关于细胞抑制药物药代动力学行为的信息是其临床应用成功的先决条件，但仅凭这一点不足以预测肿瘤反应。
